{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:08:49Z","timestamp":1791295729978,"version":"4.1.0"},"reference-count":317,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1378\/chest.126.3_suppl.234s","type":"journal-article","created":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T18:47:46Z","timestamp":1095792466000},"page":"234S-264S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":495,"special_numbering":"S","title":["Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects"],"prefix":"10.1016","volume":"126","author":[{"given":"Carlo","family":"Patrono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Coller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garret A.","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.126.3_suppl.234S_bib1","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","article-title":"Platelet-active drugs: the relationships among dose, effectiveness, and side effects","volume":"119","author":"Patrono","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-136-2-200201150-00015","article-title":"Aspirin for the primary prevention of cardiovascular events: recommendation and rationale","volume":"136","author":"US Preventive Services Task Force","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib3","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMcp012672","article-title":"Aspirin for primary prevention of coronary events","volume":"346","author":"Lauer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.CIR.0000020190.45892.75","article-title":"AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update; consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases","volume":"106","author":"Pearson","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib5","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.103.21.2572","article-title":"Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-assessing ultegra) multicenter study","volume":"103","author":"Steinhubl","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2796.2002.01027.x","article-title":"Individual variations of platelet inhibition after loading doses of clopidogrel","volume":"252","author":"Jaremo","year":"2002","journal-title":"J Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib6A","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib8","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0002-9149(02)02718-2","article-title":"Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin","volume":"90","author":"Sane","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0037-1613462","article-title":"Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement","volume":"89","author":"Muller","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib10A","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib10B","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/S0195-668X(03)00442-1","article-title":"Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study","volume":"24","author":"Neubauer","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.234S_bib11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0140-6736(01)06585-0","article-title":"Acute coronary syndrome without ST elevation: implementation of new guidelines","volume":"358","author":"Hamm","year":"2001","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial","volume":"357","author":"GUSTO IV-ACS Investigators","year":"2001","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib15","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.234S_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.234S_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/art.10738","article-title":"Selective cyclooxygenase-2 inhibitors, aspirin and cardiovascular disease: a reappraisal","volume":"48","author":"Baigent","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1378\/chest.126.3_suppl.234S_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients","volume":"324","author":"Antithrombotic Trialists Collaboration","year":"2002","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.234S_bib20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib21","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","article-title":"Acetylation of prostaglandin synthase by aspirin","volume":"72","author":"Roth","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.234S_bib22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI108941","article-title":"Inhibition of platelet prostaglandin synthetase by oral aspirin","volume":"61","author":"Burch","year":"1979","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib23","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1172\/JCI111110","article-title":"Arachidonate metabolism in vascular disorders","volume":"72","author":"Majerus","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib24","doi-asserted-by":"crossref","first-page":"33157","DOI":"10.1074\/jbc.271.52.33157","article-title":"Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2","volume":"271","author":"Smith","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.234S_bib25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","article-title":"The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2synthase","volume":"2","author":"Loll","year":"1995","journal-title":"Nat Struct Biol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/01.CIR.96.4.1109","article-title":"Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina","volume":"96","author":"Cipollone","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM198101083040203","article-title":"Inhibition of prostacyclin and platelet thromboxane A2after low-dose aspirin","volume":"304","author":"Preston","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib28","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib29","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1172\/JCI110814","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man","volume":"71","author":"FitzGerald","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJM198304073081402","article-title":"Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients","volume":"308","author":"Weksler","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib31","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","article-title":"Aspirin as an antiplatelet drug","volume":"330","author":"Patrono","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib33","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199110173251605","article-title":"Suppression of thromboxane A2but not systemic prostacyclin by controlled-release aspirin","volume":"325","author":"Clarke","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.234S_bib35","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1073\/pnas.93.19.10417","article-title":"Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress","volume":"93","author":"Topper","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.234S_bib36","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/41780","article-title":"Altered pain perception and inflammatory response in mice lacking prostacyclin receptor","volume":"388","author":"Murata","year":"1997","journal-title":"Nature"},{"key":"10.1378\/chest.126.3_suppl.234S_bib37","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclo-oxygenase","volume":"311","author":"Pedersen","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0022-3565(25)12907-8","article-title":"Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase","volume":"277","author":"McAdam","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1378\/chest.126.3_suppl.234S_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3181\/00379727-163-40716","article-title":"The effects of aspirin on megakaryocyte prostaglandin production","volume":"163","author":"Demers","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib40","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1073\/pnas.75.10.5181","article-title":"Sensitivity of fatty acid cyclo-oxygenase from human aorta to acetylation by aspirin","volume":"75","author":"Burch","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.234S_bib41","first-page":"196","article-title":"The role of prostaglandins in platelet function","volume":"16","author":"Burch","year":"1979","journal-title":"Semin Hematol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0049-3848(80)90334-5","article-title":"Possible significance of small numbers of functional platelets in a population of aspirin-treated plateletsin vitroandin vivo","volume":"18","author":"Cerskus","year":"1980","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.234S_bib43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(68)92228-9","article-title":"Effects of salicylates on human platelets","volume":"1","author":"O'Brien","year":"1968","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","author":"RISC Group","year":"1990","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib45","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","article-title":"Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris","volume":"340","author":"Juul-Moller","year":"1992","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib46","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0140-6736(91)92233-R","article-title":"Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events","volume":"338","author":"SALT Collaborative Group","year":"1991","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib47","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/01.STR.24.8.1125","article-title":"Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial","volume":"24","author":"Lindblad","year":"1993","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.1378\/chest.126.3_suppl.234S_bib49","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bmj.280.6213.514","article-title":"Prevention of venous thrombo-embolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression","volume":"280","author":"McKenna","year":"1980","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.234S_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2106\/00004623-198264010-00010","article-title":"High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement","volume":"64","author":"Harris","year":"1982","journal-title":"J Bone Joint Surg Am"},{"key":"10.1378\/chest.126.3_suppl.234S_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2106\/00004623-198567010-00008","article-title":"Prophylaxis of deep vein thrombosis after total hip replacement: dextran and external compression compared with 1.2 or 0.3 gram of aspirin daily","volume":"67","author":"Harris","year":"1985","journal-title":"J Bone Joint Surg"},{"key":"10.1378\/chest.126.3_suppl.234S_bib52","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results","volume":"54","author":"Farrel","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1378\/chest.126.3_suppl.234S_bib53","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","article-title":"A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke","volume":"325","author":"Dutch TIA Trial Study Group","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib54","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0140-6736(99)05388-X","article-title":"Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial","volume":"353","author":"Taylor","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib55","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib56","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Theroux","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib57","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulfinpyrazone, or both in unstable angina","volume":"313","author":"Cairns","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib58","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(84)92446-2","article-title":"Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation","volume":"1","author":"Lorenz","year":"1984","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib59","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1161\/01.CIR.77.6.1324","article-title":"Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration cooperative study","volume":"77","author":"Goldman","year":"1988","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/01.CIR.72.1.138","article-title":"Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery","volume":"72","author":"Brown","year":"1985","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib61","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199308193290802","article-title":"A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement","volume":"329","author":"Turpie","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib62","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-5223(19)40105-0","article-title":"Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves","volume":"72","author":"Altman","year":"1976","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1378\/chest.126.3_suppl.234S_bib63","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0002-9149(83)90673-2","article-title":"Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole","volume":"51","author":"Chesebro","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0002-8703(77)80351-7","article-title":"Prevention of arterial thromboembolism with acetylsalicylic acid: a controlled clinical study in patients with aortic ball valves","volume":"94","author":"Dale","year":"1977","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.234S_bib65","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM197909133011103","article-title":"Prevention of thrombosis in patients on hemodialysis by low-dose aspirin","volume":"301","author":"Harter","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib66","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","author":"ISIS-2 Collaborative Group","year":"1988","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.STR.14.1.5","article-title":"\u201cAICLA\u201d controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia","volume":"14","author":"Bousser","year":"1983","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJM197807132990201","article-title":"A randomized trial of aspirin and sulfinpyrazone in threatened stroke","volume":"299","author":"Canadian Cooperative Study Group","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib69","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/01.STR.8.3.301","article-title":"Controlled trial of aspirin in cerebral ischemia","volume":"8","author":"Fields","year":"1977","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib70","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke","volume":"349","author":"International Stroke Trial Collaborative Group","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib71","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke","volume":"349","author":"CAST (Chinese Acute Stroke Trial) Collaborative Group","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib72","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood.V83.4.885.885","article-title":"Aspirin, platelets and thrombosis: theory and practice","volume":"83","author":"Roth","year":"1994","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.234S_bib73","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib74","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI111865","article-title":"Effect of platelet-modifying drugs on arterial thromboembolism in baboons: aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition","volume":"75","author":"Hanson","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib75","doi-asserted-by":"crossref","first-page":"21B","DOI":"10.1016\/S0735-1097(86)80004-3","article-title":"Pharmacology of platelet inhibitors","volume":"8","author":"Harker","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0049-3848(82)90127-X","article-title":"Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase","volume":"25","author":"Buchanan","year":"1982","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.234S_bib77","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1172\/JCI113020","article-title":"Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclo-oxygenase inhibition","volume":"79","author":"Gaspari","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib78","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/01.CIR.85.3.1077","article-title":"High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation","volume":"85","author":"Ratnatunga","year":"1992","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib79","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0022-3565(25)21331-3","article-title":"Aspirin acetylates fibrinogen and enhances fibrinolysis: fibrinolytic effect is independent of changes in plasminogen activator levels","volume":"250","author":"Bjornsson","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1378\/chest.126.3_suppl.234S_bib80","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM197703102961001","article-title":"Increased blood fibrinolytic activity after aspirin ingestion","volume":"296","author":"Moroz","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib81","first-page":"394","article-title":"Fibrinolytic activity after administration of diflunisal and aspirin: a double-blind, randomized, placebo-controlled clinical trial","volume":"13","author":"Green","year":"1983","journal-title":"Haemostasis"},{"key":"10.1378\/chest.126.3_suppl.234S_bib82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-3565(25)25723-8","article-title":"Influence of acetylsalicylic acid and salicylamide on the coagulation of blood","volume":"128","author":"Quick","year":"1960","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1378\/chest.126.3_suppl.234S_bib83","first-page":"239","article-title":"Dose-dependent influence of acetylsalicylic acid on platelet functions and plasmatic coagulation factors","volume":"5","author":"Loew","year":"1976","journal-title":"Haemostasis"},{"key":"10.1378\/chest.126.3_suppl.234S_bib84","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0038-1648815","article-title":"Measurement of thrombin generation in whole blood: the effect of heparin and aspirin","volume":"72","author":"Kessels","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib85","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1182\/blood.V80.8.2006.2006","article-title":"Antiplatelet drugs and generation of thrombin in clotting blood","volume":"80","author":"Szczeklik","year":"1992","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.234S_bib86","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1021\/bi00289a010","article-title":"Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase","volume":"22","author":"Roth","year":"1983","journal-title":"Biochemistry"},{"key":"10.1378\/chest.126.3_suppl.234S_bib87","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/367243a0","article-title":"The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1","volume":"367","author":"Picot","year":"1994","journal-title":"Nature"},{"key":"10.1378\/chest.126.3_suppl.234S_bib88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/219068a0","article-title":"In vitroacetylation of plasma proteins, enzymes and DNA by aspirin","volume":"219","author":"Pinckard","year":"1969","journal-title":"Nature"},{"key":"10.1378\/chest.126.3_suppl.234S_bib89","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1161\/01.ATV.16.8.948","article-title":"Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia","volume":"16","author":"Szczeklik","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib90","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199108153250701","article-title":"Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis","volume":"325","author":"North American Symptomatic Carotid Endarterectomy Trial Collaborators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib91","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.STR.27.4.588","article-title":"Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts","volume":"27","author":"Barnett","year":"1996","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib92","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians' Health Study","volume":"321","author":"Steering Committee of the Physicians' Health Study Research Group","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib93","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib94","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1161\/01.CIR.91.7.2080","article-title":"Effects of aspirin on platelet-neutrophil interactions: role of nitric oxide and endothelin-1","volume":"91","author":"L\u00f3pez-Farr\u00e9","year":"1995","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.CIR.95.1.63","article-title":"Prothrombotic effects of erythrocytes on platelet reactivity: reduction by aspirin","volume":"95","author":"Santos","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib96","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/01.CIR.97.4.350","volume":"97","author":"Valles","year":"1998","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib97","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0014-5793(97)01307-0","article-title":"Aspirin protects endothelial cells from oxidative stress: possible synergism with vitamin E","volume":"417","author":"Podhaisky","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1378\/chest.126.3_suppl.234S_bib98","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/01.CIR.97.8.716","article-title":"Aspirin improves endothelial dysfunction in atherosclerosis","volume":"97","author":"Husain","year":"1998","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib98A","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1046\/j.1538-7836.2003.00284.x","article-title":"Aspirin resistance: definition, mechanisms and clinical read-outs","volume":"1","author":"Patrono","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib99","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/01.STR.24.10.1458","article-title":"Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin","volume":"24","author":"Helgason","year":"1993","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.STR.24.3.345","article-title":"Aspirin response and failure in cerebral infarction","volume":"24","author":"Helgason","year":"1993","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib101","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.STR.16.1.5","article-title":"Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia","volume":"16","author":"Weksler","year":"1985","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib103","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1055\/s-0038-1657677","article-title":"Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty","volume":"78","author":"Mueller","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib104","first-page":"221","article-title":"Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically","volume":"11","author":"Buchanan","year":"1995","journal-title":"Can J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib105","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/oxfordjournals.eurheartj.a059912","article-title":"Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease","volume":"12","author":"Berglund","year":"1991","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.234S_bib106","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0049-3848(93)90164-J","article-title":"Two-year follow-up of aspirin responder and aspirin nonresponder: a pilot-study including 180 post-stroke patients","volume":"71","author":"Grotemeyer","year":"1993","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.234S_bib107","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/01.STR.25.2.275","article-title":"Failure of aspirin treatment after stroke","volume":"25","author":"Bornstein","year":"1994","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib108","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-510X(99)00260-9","article-title":"Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study","volume":"171","author":"Chamorro","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1378\/chest.126.3_suppl.234S_bib108A","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2007-1002658","article-title":"A critical reappraisal of the bleeding time","volume":"16","author":"Rodgers","year":"1990","journal-title":"Semin Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib109","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoesis and characterizes newly formed platelets","volume":"99","author":"Rocca","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.234S_bib110","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.CIR.102.9.1007","article-title":"Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina","volume":"102","author":"Cipollone","year":"2000","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib111","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib111A","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib111B","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","article-title":"Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs","volume":"108","author":"Kurth","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib111C","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib112","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/01.STR.25.2.278","article-title":"Evidence for episodic platelet activation in acute ischemic stroke","volume":"25","author":"Van Kooten","year":"1994","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib113","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.234S_bib114","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk","volume":"351","author":"The Medical Research Council's General Practice Research Framework","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib116","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice","volume":"357","author":"Collaborative Group of the Primary Prevention Project (PPP)","year":"2001","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib117","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1056\/NEJM199003223221232","article-title":"Special report: preliminary report of the stroke prevention in atrial fibrillation study","volume":"322","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib118","first-page":"527","article-title":"Final results","volume":"84","author":"Stroke Prevention in Atrial Fibrillation Study","year":"1991","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib119","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"323","author":"The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib121","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","author":"EAFT (European Atrial Fibrillation Trial) Study Group","year":"1993","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib122","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archinte.1994.00420130030006","article-title":"Atrial fibrillation and stroke: three new studies, three remaining questions","volume":"154","author":"Albers","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib123","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial","volume":"348","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1996","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib124","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1161\/01.STR.25.7.1337","article-title":"Atrial fibrillation and stroke: revisiting the dilemmas","volume":"25","author":"Hart","year":"1994","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib125","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/jama.279.16.1273","article-title":"Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study","volume":"279","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1998","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.234S_bib126","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep veln thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial","volume":"355","author":"Pulmonary Embolism Prevention (PEP) Trial Collaborative Group","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib127","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.308.6923.235","article-title":"Collaborative overview of randomized trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.234S_bib128","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/archinte.1993.00410190057007","article-title":"Prophylactic agents for venous thrombosis in elective hip surgery","volume":"253","author":"Mohr","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib129","series-title":"Basic principles and clinical practice","first-page":"1331","article-title":"Prevention of venous thrombo-embolism","author":"Gallus","year":"1994"},{"key":"10.1378\/chest.126.3_suppl.234S_bib130","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1055\/s-0038-1651012","article-title":"An evaluation of impedance plethysmography and I-125-fibrinogen leg scanning in patients following hip surgery","volume":"62","author":"Cruickshank","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib131","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/archinte.1989.00390040013003","article-title":"A randomized trial of less intensive post-operative warfarin and aspirin therapy in the prevention of venous thrombo-embolism after surgery for fractured hip","volume":"149","author":"Powers","year":"1989","journal-title":"Arch Intern Med"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.234S_bib132","first-page":"118S","article-title":"RD Heparin (ardeparin sodium) vs aspirin to prevent deep venous thrombosis after hip or knee replacement surgery [abstract]","volume":"102","author":"Graor","year":"1992","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib133","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/01.CIR.93.1.80","article-title":"The low molecular weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism following surgery for hip fracture","volume":"93","author":"Gent","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib134","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0140-6736(00)02104-8","article-title":"Place of aspirin in prophylaxis of venous thromboembolism","volume":"355","author":"Sors","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/jama.1991.03470020086038","article-title":"A meta-analysis of low dose aspirin for the prevention of pregnancy-induced hypertensive disease","volume":"266","author":"Imperiale","year":"1991","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.234S_bib136","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0140-6736(91)93124-R","article-title":"Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial","volume":"337","author":"Uzan","year":"1991","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib137","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/0140-6736(93)92988-6","article-title":"Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension","volume":"341","author":"Italian Study of Aspirin in Pregnancy","year":"1993","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib138","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1056\/NEJM199310213291701","article-title":"Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women","volume":"329","author":"Sibai","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib139","first-page":"619","article-title":"CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9,364 pregnant women","volume":"343","author":"CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group","year":"1994","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1471-0528.1996.tb09513.x","article-title":"ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high-risk pregnant women","volume":"103","author":"Estudo Colaborativo para Prevenc\u00e0o da Pr\u00e9-eclampsia com Aspirina Collaborative Group","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib141","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1471-0528.1998.tb10088.x","article-title":"Barbados Low dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications","volume":"105","author":"Rotchell","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib142","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1471-0528.1998.tb10089.x","article-title":"A randomised trial of low dose aspirin for primiparae in pregnancy: the Jamaica Low Dose Aspirin Study Group","volume":"105","author":"Golding","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib143","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM199803123381101","article-title":"Low-dose aspirin to prevent preeclampsia in women at high risk","volume":"338","author":"Caritis","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib144","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/bmj.322.7282.329","article-title":"Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review","volume":"322","author":"Duley","year":"2001","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.234S_bib145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2125.1993.tb05689.x","article-title":"The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials","volume":"35","author":"Roderick","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib146","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archinte.158.1.33","article-title":"Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs","volume":"158","author":"Garc\u00eda Rodr\u00edguez","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib147","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.234S_bib148","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies","volume":"52","author":"Garc\u00eda Rodr\u00edguez","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib149","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib150","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","article-title":"Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product","volume":"348","author":"Kelly","year":"1996","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-1-1","article-title":"Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations","volume":"1","author":"De Abajo","year":"2001","journal-title":"BMC Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib152","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs","volume":"388","author":"Yeomans","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib153","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs","volume":"338","author":"Hawkey","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib153A","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJM200103293441304","article-title":"Preventing recurrent upper gastrointestinal bleeding in patients withHelicobacter pyloriinfection who are taking low-dose aspirin or naproxen","volume":"344","author":"Chan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib154","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1161\/01.STR.30.9.1764","article-title":"Prospective study of aspirin use and risk of stroke in women","volume":"30","author":"Iso","year":"1999","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib155","first-page":"244","article-title":"The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease","volume":"15","author":"Men\u00e8","year":"1995","journal-title":"Semin Nephrol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib156","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM198902163200703","article-title":"Improvement of renal function with selective thromboxane antagonism in lupus nephritis","volume":"320","author":"Pierucci","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib157","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0735-1097(97)00502-0","article-title":"Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial","volume":"31","author":"Al-Khadra","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib158","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0735-1097(00)00638-0","volume":"35","author":"Latini","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib158A","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00004872-200205000-00038","article-title":"Low-dose aspirin does not interefere with the blood pressure-lowering effects of antihypertensive therapy","volume":"20","author":"Zanchetti","year":"2002","journal-title":"J Hypertens"},{"key":"10.1378\/chest.126.3_suppl.234S_bib158B","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(02)11138-X","article-title":"Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review","volume":"360","author":"Teo","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib159","series-title":"Cardiovascular thrombosis-thrombocardiology, thromboneurology","first-page":"121","article-title":"Antiplatelet drugs","author":"FitzGerald","year":"1998"},{"key":"10.1378\/chest.126.3_suppl.234S_bib160","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI112341","article-title":"Estimated rate of thromboxane secretion into the circulation of normal humans","volume":"77","author":"Patrono","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib161","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","article-title":"Inhibition of thromboxane formationin vivoandex vivo: implications for therapy with platelet inhibitory drugs","volume":"69","author":"Reilly","year":"1987","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.234S_bib162","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00001648-200007000-00004","article-title":"Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women","volume":"11","author":"Garc\u00eda Rodr\u00edguez","year":"2000","journal-title":"Epidemiology"},{"key":"10.1378\/chest.126.3_suppl.234S_bib163","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archinte.162.10.1099","article-title":"Nonsteroidal anti-inflammatory drug use and acute myocardial infarction","volume":"162","author":"Solomon","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib164","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(02)07370-1","article-title":"Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study","volume":"359","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib165","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/archinte.162.10.1105","article-title":"Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis","volume":"162","author":"Watson","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib166","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archinte.162.10.1111","article-title":"Association between naproxen use and protection against acute myocardial infarction","volume":"162","author":"Rahme","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib167","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/clpt.1985.8","article-title":"Cyclooxygenase inhibition, platelet function and drug metabolite formation during chronic administration of sulfinpyrazone in man","volume":"37","author":"Pedersen","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.234S_bib168","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF02657071","article-title":"Effects of indobufen on platelet thromboxane B2production in patients with myocardial infarction","volume":"39","author":"Rebuzzi","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib169","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/01.ATV.13.9.1346","article-title":"Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus","volume":"13","author":"Dav\u00ed","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1378\/chest.126.3_suppl.234S_bib170","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0022-5223(94)70392-2","article-title":"Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency 1 year after coronary artery bypass grafting","volume":"107","author":"Rajah","year":"1994","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1378\/chest.126.3_suppl.234S_bib171","first-page":"897","article-title":"Indobufen versus aspirin plus dipyridamole after coronary artery surgery","volume":"2","author":"SINBA Group","year":"1991","journal-title":"Coron Artery Dis"},{"key":"10.1378\/chest.126.3_suppl.234S_bib172","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/01.CIR.87.1.162","article-title":"Indobufen in the prevention of thrombo-embolic complications in patients with heart disease","volume":"87","author":"Fornaro","year":"1993","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib173","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.STR.28.5.1015","article-title":"Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation","volume":"28","author":"Morocutti","year":"1997","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib174","first-page":"33","article-title":"A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study): Ticlopidine Indobufen Stroke Study","volume":"12","author":"Bergamasco","year":"1997","journal-title":"Funct Neurol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib175","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/eurheartj\/14.7.951","article-title":"Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: the Flurbiprofen French Trial","volume":"14","author":"Brochier","year":"1993","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.234S_bib176","first-page":"344","article-title":"Pharmacokinetics of triflusal after single and repeated doses in man","volume":"28","author":"Ramis","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib177","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/euhj.1999.1874","article-title":"randomized comparative trial of triflusal and aspirin following acute myocardial infarction","volume":"21","author":"Cruz-Fernandez","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.234S_bib177A","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.STR.0000063141.24491.50","article-title":"Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP Study: a randomized, double-blind, multicenter trial","volume":"34","author":"Mat\u00edas-Guiu","year":"2003","journal-title":"Stroke"},{"key":"10.1378\/chest.126.3_suppl.234S_bib178","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatorydrugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.234S_bib179","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib180","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/hc4401.100078","article-title":"Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib","volume":"104","author":"Konstam","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib181","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9149(01)02265-2","article-title":"Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac","volume":"89","author":"White","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib182","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1056\/NEJM198705143162005","article-title":"Dipyridamole","volume":"316","author":"FitzGerald","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib183","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2125.1990.tb03763.x","article-title":"Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole bloodex vivo.","volume":"30","author":"M\u00fcller","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib184","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1742-1241.2001.tb11007.x","article-title":"European Stroke Prevention Study 2: cardiac safety in the European Stroke Prevention Study 2 (ESPS2)","volume":"55","author":"Diener","year":"2001","journal-title":"Int J Clin Pract"},{"key":"10.1378\/chest.126.3_suppl.234S_bib185","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/01.CIR.100.15.1667","article-title":"Ticlopidine and clopidogrel","volume":"100","author":"Quinn","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib186","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib186A","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2002-10-3027","article-title":"Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues Cys17 and Cys270","volume":"101","author":"Ding","year":"2003","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.234S_bib187","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1378\/chest.126.3_suppl.234S_bib187A","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1073\/pnas.0437879100","article-title":"Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding","volume":"100","author":"Cattaneo","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.234S_bib188","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.CIR.82.1.17","article-title":"Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial","volume":"82","author":"Balsano","year":"1990","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib189","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"2","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib190","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients","volume":"321","author":"Hass","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib191","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0735-1097(01)01164-0","article-title":"Ticlopidine versus aspirin after myocardial infarction (STAMI) trial","volume":"37","author":"Scrutinio","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib192","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/000331978803900904","article-title":"Multicenter double blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications","volume":"39","author":"Arcan","year":"1988","journal-title":"Angiology"},{"key":"10.1378\/chest.126.3_suppl.234S_bib193","first-page":"84","article-title":"Ticlopidine in the treatment of intermittent claudication: a 21-month double blind trial","volume":"114","author":"Balsano","year":"1989","journal-title":"J Lab Clin Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib194","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2796.1990.tb00164.x","article-title":"Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine; results from STIMS, the Swedish Ticlopidine Multicentre Study","volume":"227","author":"Janzon","year":"1990","journal-title":"J Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib195","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0022-5223(19)36194-X","article-title":"Prevention of aortocoronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rate of venous coronary bypass grafts: a double-blind study","volume":"94","author":"Limet","year":"1987","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1378\/chest.126.3_suppl.234S_bib196","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/01.CIR.82.1.296","article-title":"Ticlopidine in unstable angina: a more expensive aspirin?","volume":"82","author":"FitzGerald","year":"1990","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib197","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s002770050369","article-title":"Ticlopidine-associated aplastic anemia: a case report and review of literature","volume":"76","author":"Yeh","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib198","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/archinte.159.21.2524","article-title":"Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention","volume":"159","author":"Bennett","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib199","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1055\/s-0038-1650529","article-title":"The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat","volume":"76","author":"Herbert","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/107602969700300405","article-title":"Antiplatelet effects of the addition of acetylsalicylic acid 40 mg daily to ticlopidine in human healthy volunteers","volume":"3","author":"Lecompte","year":"1997","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib201","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib202","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(97)22003-9","article-title":"Antiplatelet rather than anticoagulant therapy with coronary stenting","volume":"349","author":"More","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0735-1097(01)01713-2","article-title":"Meta-analysis of randomized and registry comparisons of ticlopidine with clopidorel after stenting","volume":"39","author":"Bhatt","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib204","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.281.9.806","article-title":"Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting: EPISTENT Investigators; Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting","volume":"281","author":"Steinhubl","year":"1999","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.234S_bib205","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1527-3466.1993.tb00275.x","article-title":"Clopidogrel, a novel antiplatelet and antithrombotic agent","volume":"11","author":"Herbert","year":"1993","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1378\/chest.126.3_suppl.234S_bib206","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib207","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1124\/dmd.30.11.1288","article-title":"Structure and stereochemistry of the active metabolite of clopidogrel","volume":"30","author":"Pereillo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1378\/chest.126.3_suppl.234S_bib207A","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.31.1.53","article-title":"The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin","volume":"31","author":"Clarke","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1378\/chest.126.3_suppl.234S_bib208","first-page":"15","article-title":"Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects","volume":"25","author":"Savcic","year":"1999","journal-title":"Semin Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib208A","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9149(03)00626-X","article-title":"Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atrovastatin versus other statin therapies","volume":"92","author":"Wienbergen","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib209","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000088780.57432.43","article-title":"Lack of adverse clopidogrel \u2013 atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial","volume":"108","author":"Saw","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib210","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","article-title":"Thrombotic thrombocytopenic purpura associated with clopidogrel","volume":"342","author":"Bennett","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib211","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib212","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1172\/JCI119307","article-title":"Platelet GPIIb\/IIIa antagonists: the first anti-integrin receptor therapeutics","volume":"99","author":"Coller","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib213","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1055\/s-0037-1615850","article-title":"Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions","volume":"82","author":"Coller","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.234S_bib213A","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0049-3848(02)00207-4","article-title":"The GPIIb\/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b\/CD18, alphasMbeta2)","volume":"107","author":"Schwarz","year":"2002","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.234S_bib214","series-title":"Clinical trials in cardiovascular disease","first-page":"166","article-title":"Platelet glycoprotein IIb\/IIIa receptor inhibitors","author":"Anderson","year":"1999"},{"key":"10.1378\/chest.126.3_suppl.234S_bib215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","article-title":"Platelet GPIIb\/IIIa blockers","volume":"353","author":"Topol","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib216","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.100.4.437","article-title":"Platelet glycoprotein IIb\/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use?","volume":"100","author":"Scarborough","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib217","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1161\/01.ATV.19.12.2835","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors: basic and clinical aspects","volume":"19","author":"Nurden","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib218","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1172\/JCI110973","article-title":"A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and\/or IIIa","volume":"72","author":"Coller","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib219","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1161\/01.CIR.90.4.1757","article-title":"Pharmacodynamics of chimeric glycoprotein IIb\/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty","volume":"90","author":"Tcheng","year":"1994","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib220","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.97.17.1680","article-title":"Pharmacodynamic profile of a short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb\/IIIa receptor blockade","volume":"97","author":"Mascelli","year":"1998","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib221","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib222","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(94)90007-8","article-title":"Randomised trial of coronary intervention with antibody against platelet IIb\/IIIa integrin for reduction of clinical restenosis: results at 6 months","volume":"343","author":"Topol","year":"1994","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib223","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib224","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1161\/01.CIR.100.25.2477","article-title":"Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting Trial) diabetic substudy","volume":"100","author":"Marso","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib225","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1161\/01.CIR.102.13.1490","article-title":"Flow cytometric monitoring of glycoprotein IIb\/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine","volume":"102","author":"Peter","year":"2000","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib226","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1023\/A:1022058103581","article-title":"Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb\/IIIa antagonists in non-human primates","volume":"14","author":"Nakada","year":"2002","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.234S_bib227","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.99.17.2231","article-title":"Quantifying GPIIb\/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists","volume":"99","author":"Quinn","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib228","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0735-1097(00)01181-5","article-title":"Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function","volume":"37","author":"Lev","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib229","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/01.CIR.99.5.620","article-title":"Rapid platelet-function assay (RPFA): an automated and quantitative cartridge-based method","volume":"99","author":"Smith","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib230","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0735-1097(01)01165-2","article-title":"Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting","volume":"37","author":"Neumann","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib231","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1008931126871","article-title":"Efficacy of abciximab induced platelet blockade using a rapid point of care assay","volume":"7","author":"Kereiakes","year":"1999","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.234S_bib232","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/01.CIR.100.19.1977","article-title":"Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention","volume":"100","author":"Steinhubl","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib233","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1023\/A:1018724827741","article-title":"Applications of anti-platelet monitoring in catheterization laboratory","volume":"9","author":"Mukherjee","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.234S_bib234","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0002-9149(96)00582-6","article-title":"Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion","volume":"78","author":"Kereiakes","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib235","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/01.CIR.95.4.809","article-title":"Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy","volume":"95","author":"Berkowitz","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib236","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/hj.1999.v138.a100465","article-title":"Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitori","volume":"138","author":"Madan","year":"1999","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.234S_bib237","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood.V99.6.2054","article-title":"Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets","volume":"99","author":"Curtis","year":"2002","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.234S_bib238","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/146288401753514515","article-title":"Delayed thrombocytopenia following abciximab therapy","volume":"4","author":"Kaluski","year":"2001","journal-title":"Int J Cardiovasc Intervent"},{"key":"10.1378\/chest.126.3_suppl.234S_bib238A","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/107424840200700i103","article-title":"Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro)","volume":"7","author":"Sharma","year":"2002","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.234S_bib238B","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/hc3301.094533","article-title":"Abciximab readministration: results of the ReoPro Readministration Registry","volume":"104","author":"Tcheng","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib239","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9149(99)00768-7","article-title":"Efficacy of abciximab readministration in coronary intervention","volume":"85","author":"Madan","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib239A","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0002-8703(03)00231-X","article-title":"Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions","volume":"146","author":"Best","year":"2003","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.234S_bib240","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI118859","article-title":"Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse\/human chimeric 7E3 antibody: potential implications for effect of c7E3 Fab treatment on acute thrombosis and \u201cclinical restenosis.\u201d","volume":"98","author":"Reverter","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.234S_bib241","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1021\/jm00102a020","article-title":"Non-peptide fibrinogen receptor antagonists: I. Discovery and design of exosite inhibitors","volume":"35","author":"Hartman","year":"1992","journal-title":"J Med Chem"},{"key":"10.1378\/chest.126.3_suppl.234S_bib242","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1021\/jm00042a007","article-title":"Non-peptide fibrinogen receptor antagonists: II. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp","volume":"37","author":"Egbertson","year":"1994","journal-title":"J Med Chem"},{"key":"10.1378\/chest.126.3_suppl.234S_bib243","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S0090-9556(24)14939-2","article-title":"In vitroandin vivostudies on the metabolism of tirofiban","volume":"27","author":"Vickers","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1378\/chest.126.3_suppl.234S_bib243A","series-title":"Tirofiban [package insert]","year":"2002"},{"key":"10.1378\/chest.126.3_suppl.234S_bib244","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.1994.152","article-title":"Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb\/IIIa receptor antagonist, in healthy men","volume":"56","author":"Barrett","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.234S_bib245","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.CIR.88.4.1512","article-title":"MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb\/IIIa antagonist, is active in man","volume":"88","author":"Peerlinck","year":"1993","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib246","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0735-1097(95)00500-5","article-title":"Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb\/IIIa blockade in high-risk patients undergoing coronary angioplasty","volume":"27","author":"Kereiakes","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib247","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0002-9149(99)00321-5","article-title":"Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention","volume":"84","author":"Kereiakes","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib248","first-page":"425","article-title":"A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban","volume":"52","author":"Simon","year":"2001","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.126.3_suppl.234S_bib249","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1161\/01.CIR.0000029744.01096.1F","volume":"106","author":"Batchelor","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1008904310194","article-title":"Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb\/IIIa receptor antagonists in renal failure","volume":"11","author":"Smith","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.234S_bib251","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1161\/01.CIR.0000016359.94919.16","volume":"105","author":"Januzzi","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib252","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V94.2.587","article-title":"Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb\/IIIa","volume":"94","author":"Bednar","year":"1999","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.234S_bib253","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.V100.6.2071","article-title":"Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb\/IIIa","volume":"100","author":"Bougie","year":"2002","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.234S_bib254","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0021-9258(18)54042-4","article-title":"Design of potent and specific integrin antagonists: peptide antagonists with high specificity for glycoprotein IIb-IIIa","volume":"268","author":"Scarborough","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.234S_bib255","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1161\/hc3101.092199","article-title":"Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin","volume":"104","author":"Lele","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib256","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1161\/01.CIR.96.5.1488","article-title":"Effect of Ca2+on GP IIb-IIIa interactions with Integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate","volume":"96","author":"Phillips","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib257","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0149-2918(98)80094-5","article-title":"Disposition of 14C-eptifibatide after intravenous administration to healthy men","volume":"20","author":"Alton","year":"1998","journal-title":"Clin Ther"},{"key":"10.1378\/chest.126.3_suppl.234S_bib258","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9149(02)02991-0","article-title":"Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)","volume":"91","author":"Reddan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib259","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/hc2901.093504","article-title":"Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention","volume":"104","author":"Gilchrist","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib260","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/S0002-9149(97)00572-9","article-title":"Clinical pharmacology of eptifibatide","volume":"80","author":"Phillips","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib261","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1067\/mhj.2001.116962","article-title":"Comparative efficacy of fibrinogen and platelet supplementation on thein vitroreversibility of competitive glycoprotein IIb\/IIIa (alphaIIb\/beta3) receptor-directed platelet inhibition","volume":"142","author":"Li","year":"2001","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.234S_bib262","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1161\/01.CIR.91.8.2151","article-title":"Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb\/IIIa blocker integrelin in elective coronary intervention","volume":"91","author":"Tcheng","year":"1995","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib263","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II","volume":"349","author":"IMPACT-II Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib264","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0002-9149(99)80345-2","article-title":"Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb\/IIIa inhibitor during percutaneous intervention","volume":"76","author":"Harrington","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib265","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/hc2901.093500","article-title":"Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT","volume":"104","author":"Tardiff","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib266","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib267","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","author":"ESPRIT Investigators (Enhanced Suppression of the Platelet IIb\/IIIa Receptor with Integrilin Therapy)","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib268","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1001\/jama.285.19.2468","article-title":"Platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial","volume":"285","author":"O'Shea","year":"2001","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.234S_bib269","first-page":"76","article-title":"Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension","volume":"58","author":"Rezkalla","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.126.3_suppl.234S_bib270","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","author":"RESTORE Investigators","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib271","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study","volume":"349","author":"CAPTURE Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib272","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib273","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9343(02)01145-2","article-title":"Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization","volume":"113","author":"Topol","year":"2002","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib274","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib275","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib276","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(02)09605-8","article-title":"Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: the TARGET follow-up study","volume":"360","author":"Moliterno","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib277","first-page":"I","article-title":"A randomized trial of potent platelet IIb\/IIIa antagonism, heparin, or both in patients with unstable angina: the PARAGON study [abstract]","volume":"94","author":"PARAGON Investigators","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib278","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib279","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib280","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/hc0302.102573","article-title":"Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes","volume":"105","author":"Platelet IIb\/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON)-B Investigators","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib281","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1161\/hc4801.100029","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes","volume":"104","author":"Roffi","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib282","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1161\/01.CIR.99.21.2720","article-title":"Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial: the TIMI 14 Investigators","volume":"99","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib283","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(00)05059-5","article-title":"Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb\/IIIa inhibition: the GUSTO V randomised trial","volume":"357","author":"GUSTO V Investigators","year":"2001","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib284","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1001\/jama.288.17.2130","article-title":"Mortality at 1 year with combination platelet glycoprotein IIb\/IIIa inhibition and reduce-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial","volume":"288","author":"Lincoff","year":"2002","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.234S_bib285","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.CIR.96.1.76","article-title":"First chronic platelet glycoprotein IIb\/IIIa integrin blockade: a randomized, placebo-controlled study of xemilofiban in unstable angina with percutaneous coronary interventions","volume":"96","author":"Simpfendorfer","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib286","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","article-title":"Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization","volume":"342","author":"O'Neill","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.234S_bib287","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","article-title":"Oral glycoprotein IIb\/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial","volume":"102","author":"Cannon","year":"2000","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib288","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(99)11179-6","article-title":"Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial","volume":"355","author":"SYMPHONY Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.234S_bib289","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/01.CIR.103.13.1727","article-title":"Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes","volume":"103","author":"Second SYMPHONY Investigators","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib289A","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.CIR.0000084501.48570.F6","article-title":"Randomized, double-blind, placebo-controlled, international trial of the oral IIb\/IIIa antagonist lotrafiban in coronary and cerebrovascular disease","volume":"108","author":"Topol","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib290","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.103.2.201","article-title":"Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.234S_bib291","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/euhj.2001.2751","article-title":"Oral glycoprotein IIb\/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable","volume":"23","author":"Leebeek","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.234S_bib292","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1182\/blood.V92.9.3240","article-title":"Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb\/IIIa (\u03b1IIb\u03b23) inhibitors","volume":"92","author":"Peter","year":"1998","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.234S_bib293","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0735-1097(00)00919-0","article-title":"Evidence of platelet activation during treatment with a GPIIb\/IIIa antagonist in patients presenting with acute coronary syndromes","volume":"36","author":"Cox","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib294","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9149(99)00778-X","article-title":"Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy","volume":"85","author":"Holmes","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.234S_bib295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.CIR.97.1.5","article-title":"Monitoring platelet GP IIb\/IIIa antagonist therapy","volume":"97","author":"Coller","year":"1998","journal-title":"Circulation"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215314938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215314938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:53:19Z","timestamp":1757919199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215314938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":317,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0012369215314938"],"URL":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.234s","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.234S","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}